Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03886311
Title Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma (TNT)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sarcoma Oncology Research Center, LLC
Indications

sarcoma

desmoid tumor

chordoma

Therapies

Nivolumab + Talimogene laherparepvec + Trabectedin

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.